Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effects of naltrexone in active Crohn's disease

Trial Profile

The effects of naltrexone in active Crohn's disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naltrexone (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use

Most Recent Events

  • 31 May 2017 According to an Immune Therapeutics media release, The company is ready to submit a New Drug Application (NDA) to the Directorate of Pharmacy and Medicines. The application will include results of four phase II clinical trials and one bridging trial clinical trial.
  • 01 May 2010 Results presented at 2010 Digestive Disease Week.
  • 11 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top